Blog

COMP360 psilocybin therapy shows potential in open-label study in type II bipolar disorder presented at ACNP

Dec 8 • 8 min read

COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced that new positive data demonstrating the potential of COMP360 psilocybin therapy in depression have been presented at the Annual Meeting of the American College of Neuropsychopharmacology (ACNP). The results were presented from…

Red Light Holland’s Wholly Owned Subsidiary, Radix Motion, Receives Favorable International Preliminary Report on Patentability on its Patent Application: Utilizing 3D Movement Data for Psychedelic Therapy

Dec 7 • 3 min read

Red Light Holland Corp. (CSE: TRIP | FSE: 4YX | OTC Pink: TRUFF), an Ontario-based corporation engaged in the production, growth and sale of a premium brand of magic truffles to the legal, recreational market within the Netherlands, is pleased to announce that its wholly owned subsidiary, Radix Motion Inc., has received an International Preliminary…

Ehave Shareholder from CEO Ben Kaplan and Corporate Update

Dec 7 • 7 min read

Ehave, Inc., (OTC Pink: EHVVF), a Healthcare Analytics provider with interests in the psychedelic and mental health sectors, today issued a letter to shareholders from its Chief Executive Officer, Ben Kaplan. Dear Fellow Shareholders As 2022 draws to a close, many of us will reflect on a year that saw global economic activity experiencing a…

BetterLife Announces Closing of Private Placement

Dec 7 • 3 min read

BetterLife Pharma Inc. (CSE: BETR | OTCQB : BETRF | FRA: NPAU) is pleased to announce that it has closed a non-brokered private placement by issuing 3,160,000 common shares at a price of USD$0.15 per common share for gross proceeds of USD$474,000. The common shares issued pursuant to the Offering are subject to a hold period under applicable securities laws, which…

Reunion Neuroscience Inc. to Participate in Upcoming Investor Conferences in December

Dec 7 • 2 min read

Reunion Neuroscience Inc. (NASDAQ: REUN | TSX: REUN), a biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions, today announced it will be participating in the following investor conferences in December 2022. Stifel Canada’s The Future of Healthcare ConferenceDate: Wednesday, December 7, 2022Time: 2:00 p.m. ETFormat: PresentationWebcast: bit.ly/3AT6tFb Canaccord Genuity Symposium on New…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441442443444445446447448449450451452453454455456457458459460461462463464465466467468469470471472473474475476477478479480481482483484485486487488489490491492493494495496497498499500501502503504505506507508509510511512513514515516517518519520521522523524525526527528529530531532533534535536537538